Experiência inicial com o uso de stents eluidores de everolimus em pacientes do mundo real: seguimento clínico de um ano

Abstract

ABSTRACT Early Experience with Everolimus-Eluting Stents inReal-world Patients: One-Year Clinical Follow-Up Background: Everolimus-eluting stents have proved to besafe and effective in the treatment of low-risk, selected pa-tients, from randomized trials. Nonetheless, studies assessingtheir impact on more complex real-world patients are rare. Method: We prospectively evaluated 193 patients treatedwith everolimus-eluting stents alone. The only exclusioncriteria were: in-stent restenosis of another drug-elutingstent, percutaneous coronary intervention of a saphenousvein graft and acute myocardial infarction with ST segmentelevation. The primary endpoint was the incidence ofmajor adverse cardiac events (MACE), defined as thecomposite of cardiac death, myocardial infarction andtarget vessel revascularization. Results: Mean age was60.6 ± 11.8 years. Half of the patients were women and36.8% were diabetics. Multivessel disease was found in61.6% of the patients. Patients had 1.8 ± 0.66 lesiontreated in 1.73 ± 0.9 vessel, with a mean of 2.27 ± 0.9stents per patient. The majority (70.6%) of the lesionswere type B2/C, true bifurcations were treated in 37.3%of the cases and moderate to severe calcifications wereobserved in 17.4% of the lesions. The 1-year MACE ratewas 6.7%, mainly due to the occurrence of in-hospitalevents. There was only one (0.5%) case of probablesubacute stent thrombosis. No cases of late stent thrombosiswere observed.